HOUSTON INNOVATORS PODCAST EPISODE 72

Expert says Houston is the prime spot for creating and testing game-changing resilience solutions

Richard Seline of Houston-based Resilience Innovation Hub joins the Houston Innovators Podcast to discuss how it's time for the world to see Houston as the resilient city it is. Photo courtesy of ResilientH20

The city of Houston, along the rest of the Lone Star State, has been hit from every direction — pandemics, hurricanes, winter storms, and more.

"We're just whipsawed," says Richard Seline, co-founder at the Houston-based Resilience Innovation Hub Collaboratory. "We've gone from back-to-back storms and hurricanes to COVID to snow and ice and its impact on energy. People are just exhausted."

Now, Seline says on this week's episode of the Houston Innovators Podcast, this exhaustion is festering into frustration and anger — and calling for change. The things that need to change, Seline says, includes growing investment and innovation in resilience solutions.

"As a fourth generation Houstonian, it's just so hard to see my hometown get hit persistently with a lot of these weather and other type of disasters," Seline says.

These unprecedented disasters — which are of course occurring beyond Houston and Texas — have also sparked a growing interest in change for insurance companies that have lost a trillion dollars on the United States Gulf Coast over the past seven years, Seline says. Something has got to change regarding preparation and damage mitigation.

Creating conversations about change is exactly what Seline and the Resilience Innovation Hub, which is based out of The Cannon Tower in downtown Houston, is focused on. Following all these catastrophic events, the industry is overwhelmed with data — and now is the time to put it to use on innovation and tech solutions.

"We are drowning in data and hungry for intelligence — actionable intelligence," Seline says, adding that now innovators and entrepreneurs are taking on this data and creating solutions.

The challenge then becomes convincing decision makers to pivot from what they know and are comfortable with to what they don't know and what they aren't comfortable with.

And, Seline says on the show, that needs to happen across the board — from public and private companies to government entities and nonprofits both locally and beyond.

"I think that it's time to flip this on its head and say to the world, 'we got it.,'" Seline says. "Because we know these challenges, we are opening the world to the best ideas to be piloted and demonstrated. All I ask is that we get elective and appointed officials who are open to ideas and solutions. That's how innovation occurs."

Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News